Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
175.89
+0.25 (0.14%)
Nov 19, 2024, 3:23 PM EST - Market open
Krystal Biotech Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Krystal Biotech stock have an average target of 206, with a low estimate of 175 and a high estimate of 221. The average target predicts an increase of 17.12% from the current stock price of 175.89.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KRYS stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 7 | 6 | 6 | 4 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 9 | 9 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $204 → $206 | Hold | Maintains | $204 → $206 | +17.12% | Nov 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $221 | Strong Buy | Reiterates | $221 | +25.65% | Nov 5, 2024 |
| Stifel | Stifel | Strong Buy Maintains $204 → $220 | Strong Buy | Maintains | $204 → $220 | +25.08% | Sep 11, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Aug 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $221 | Strong Buy | Reiterates | $221 | +25.65% | Aug 29, 2024 |
Financial Forecast
Revenue This Year
296.92M
from 50.70M
Increased by 485.65%
Revenue Next Year
471.03M
from 296.92M
Increased by 58.64%
EPS This Year
2.86
from 0.39
Increased by 632.31%
EPS Next Year
6.01
from 2.86
Increased by 110.54%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 311.2M | 566.2M | 971.4M | ||
| Avg | 296.9M | 471.0M | 667.8M | ||
| Low | 274.4M | 377.3M | 499.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 513.9% | 90.7% | 106.2% | ||
| Avg | 485.7% | 58.6% | 41.8% | ||
| Low | 441.2% | 27.1% | 5.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.74 | 8.43 | 16.31 | ||
| Avg | 2.86 | 6.01 | 9.19 | ||
| Low | 1.88 | 2.95 | 4.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 858.5% | 195.2% | 171.2% | ||
| Avg | 632.3% | 110.5% | 52.8% | ||
| Low | 382.5% | 3.3% | -20.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.